Parkinson's disease is primarily caused by dysfunction of dopaminergic neurons, however,
nondopaminergic (ND) systems are also involved. ND targets are potentially useful to reduce …

… in medical history for James Parkinson's by addition of more symptoms to … Parkinson's
disease (PD) for those symptoms [4]. Being the second most familiar ND after Alzheimer's disease …

… Here, we review the existing and emerging interventions for PD with focus on newly approved
and investigational drugs for motor symptoms, motor fluctuations, dyskinesia, and balance …

Background: The majority of current pharmacological treatments for Parkinson’s disease (PD)
were approved for clinical use in the second half of the last century and they only provide …

… Movement disorders like Parkinson disease (PD) and Huntington disease (HD) rank among
… complex group of neurological illness or diseases that manifest either increase or decrease …

… Our hope is that this report will provide some insights into the different approaches to
target PD and explore emerging novel treatment options. We also aim to raise awareness …

… of neurodegenerative diseases and … diseases, like Parkinson's disease (PD). We believe
that deciphering the molecular processes and pathways underlying one of these diseases may …

… are Alzheimer's disease (AD), Parkinson's disease (PD), dementia, brain cancer, seizures,
mental disorders, and other movement disorders. The major barrier in treating CNS disease is …

Parkinson’s disease (PD) is a complicated neurodegenerative disease, of which gastrointestinal
disturbance appears prior to motor symptoms. Numerous studies have shed light on the …

… In the following section, we will discuss some emerging pharmacological PD targets with
substantial preclinical evidence (as also depicted in Table ​1) that can be further considered …